BAVARIAN NORDIC A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 184.8 DKK | +4.14% |
|
+2.69% | +4.17% |
| May. 31 | Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine | MT |
| May. 30 | Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children | MT |
| Sales 2024 * | 5.23B 761M | Sales 2025 * | 5.05B 735M | Capitalization | 14.39B 2.09B |
|---|---|---|---|---|---|
| Net income 2024 * | 689M 100M | Net income 2025 * | 947M 138M | EV / Sales 2024 * | 2.76 x |
| Net Debt 2024 * | 23.72M 3.45M | Net cash position 2025 * | 849M 123M | EV / Sales 2025 * | 2.68 x |
| P/E ratio 2024 * |
20.7
x | P/E ratio 2025 * |
15.3
x | Employees | 1,381 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.85% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bavarian Nordic A/S
More press releases
More news
| 1 day | +4.14% | ||
| 1 week | +2.69% | ||
| 1 month | +21.29% | ||
| 3 months | +19.03% | ||
| 6 months | +12.64% | ||
| Current year | +4.17% |
1 week
173.90
185.00
1 month
148.10185.00
Current year
143.40185.00
1 year
125.55222.00
3 years
115.20411.00
5 years
103.20411.00
10 years
103.20444.00
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Chaplin
CEO | Chief Executive Officer | 57 | 98-12-31 |
Henrik Juuel
DFI | Director of Finance/CFO | 59 | 18-10-31 |
Russell Thirsk
COO | Chief Operating Officer | 56 | 22-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 73 | 10-04-26 | |
| Director/Board Member | 57 | 22-12-31 | |
Frank Verwiel
BRD | Director/Board Member | 61 | 16-04-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 746 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 184.8 | +4.14% | 777,368 |
| 24-05-30 | 177.5 | +0.97% | 283,489 |
| 24-05-29 | 175.8 | -1.21% | 189,029 |
| 24-05-28 | 178 | -0.73% | 292,689 |
| 24-05-27 | 179.2 | -0.42% | 266,171 |
Delayed Quote Nasdaq Copenhagen, May 31, 2024 at 10:59 am EDT
More quotes
Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases.
Net sales by revenue source are divided between sales of products (97.8%) and services (2.2%).
Net sales are distributed geographically as follows: the United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8%), Switzerland ( 1.5%), Sweden (1%), Chile (0.9%), Taiwan (0.8%), the United Kingdom (0.6%), Hong Kong (0.2%), Saudi Arabia (0.1%), and others (4.9%).
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
184.8
DKK
Average target price
262
DKK
Spread / Average Target
+41.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.17% | 2.09B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- BAVA Stock
